Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery by McPhail, Donald et al.
Strathprints Institutional Repository
McPhail, Donald and Tetley, L. and Dufès, Christine and Uchegbu, I.F. (2000) Liposomes
encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery.
International Journal of Pharmaceutics, 200 (1). pp. 73-86. ISSN 0378-5173
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
International Journal of Pharmaceutics 200 (2000) 73–86
Liposomes encapsulating polymeric chitosan based vesicles
— a vesicle in vesicle system for drug delivery
Deborah McPhail a, Laurence Tetley b, Christine Dufes a,
Ijeoma F. Uchegbu a,*
a Department of Pharmaceutical Sciences, Uni6ersity of Strathclyde, Strathclyde Institute for Biomedical Sciences, 27 Taylor Street,
Glasgow G4 ONR, UK
b Institute of Biomedical and Life Sciences, Uni6ersity of Glasgow, Joseph Black Building, Glasgow G12 8QQ, UK
Received 31 August 1999; received in revised form 14 December 1999; accepted 17 January 2000
Abstract
Drug delivery systems comprising vesicles prepared from one amphiphile encapsulating vesicles prepared from a
second amphiphile have not been prepared previously due to a tendency of the bilayer components of the different
vesicles to mix during preparation. Recently we have developed polymeric vesicles using the new polymer-palmitoyl
glycol chitosan and cholesterol in a 2:1 weight ratio. These polymeric vesicles have now been encapsulated within egg
phosphatidylcholine (egg PC), cholesterol (2:1 weight ratio) liposomes yielding a vesicle in vesicle system. The vesicle
in vesicle system was visualised by freeze fracture electron microscopy. The mixing of the different bilayer components
was studied by monitoring the excimer fluorescence of pyrene-labelled polymeric vesicles after their encapsulation
within egg PC liposomes or hexadecyl diglycerol ether niosomes. A minimum degree of lipid mixing was observed
with the polymeric vesicle-egg PC liposome system when compared to the polymeric vesicle-hexadecyl diglycerol ether
niosome system. The polymeric vesicle-egg PC vesicle in vesicle system was shown to retard the release of
encapsulated solutes. 28% of 5(6)-carboxyfluorescein (CF) encapsulated in the polymeric vesicle compartment of the
vesicle in vesicle system was released after 4 h compared to the release of 62% of encapsulated CF from plain
polymeric vesicles within the same time period. © 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Vesicles such as liposomes, prepared from
phospholipids (Gregoriadis, 1993, 1995) and nio-
somes, prepared from non ionic surfactants (Flo-
rence, 1993; Uchegbu and Vyas, 1998) have been
studied as drug delivery systems for a number of
years. There are currently a number of commer-
cially available liposomal formulations which in-
clude liposomal doxorubicin (Doxil®)
(Winterhalter et al., 1997) and daunorubicin
(DaunoXome®) (Fox, 1995) for the treatment of
Kaposi’s sarcoma and also liposomal ampho-
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tericin (Ambisome®) (Boswell et al., 1998) for the
treatment of systemic fungal infections. These for-
mulations are beneficial in targeting drugs to the
site of pathology and away from potential sites of
toxicity with the drugs usually being encapsulated
within unilarnellar vesicles.
The production of multi-component drug deliv-
ery systems in which vesicles prepared from one
type of amphiphile encapsulate vesicles prepared
from a different amphiphile (as shown schemati-
cally in Fig. 1a) has not been attempted due to the
tendency of the different bilayer components to
mix. However solid particulate matter has been
encapsulated within vesicles (Antimisiaris et al.,
1993; Arrault et al., 1997) and vesicles have been
formulated within both water in oil emulsions
(Yoshioka and Florence, 1994) and non ionic
surfactant based organogels (Murdan et al.,
1996). It is envisaged that the encapsulation of a
drug: enzyme: vaccine: gene loaded vesicle within
a second vesicle will yield a system with improved
controlled release properties (Fig. 1b). The fabri-
cation of just such a vesicle in vesicle system using
polymeric vesicles is the subject of the current
study. Polymeric vesicles (Uchegbu et al.,
1998a,b) have been prepared by us from specially
designed amphiphilic polymers, the latter of
which are synthesised by grafting pendant hydro-
phobic (Uchegbu et al., 1998b) or hydrophobic
and hydrophilic groups (Uchegbu et al., 1998a)
on to soluble linear polymers. Polymeric vesicles
prepared from palmitoyl glycol chitosan, choles-
terol (2:1 weight ratio) (Uchegbu et al., 1998b)
have in turn been encapsulated within Egg PC,
cholesterol (2:1 weight ratio) liposomes to yield a
vesicle in vesicle system.
2. Materials and methods
2.1. Materials
Palmitoyl glycol chitosan (Fig. 2) was synthe-
sised and characterised as previously described
(Uchegbu et al., 1998b). Cholesterol, dicetyl phos-
phate, phosphatidy1cho line, 10(1-pyrene) de-
canoic acid, 5(6)-carboxyfluorescein and gold
chloride were all supplied by Sigma Chemical Co.,
UK. Dicetyl phosphate was supplied by Fluka
Chemical, UK. All organic solvents and phos-
phate buffered saline tablets were supplied by
Merck Chemical Co., UK. Hexadecyl diglycerol
ether (C16G2) was a kind gift from L’Oreal,
France. Colloidal gold (20nm) was manufactured
by sodium citrate reduction of gold chloride
(Mey, 1983).
2.2. Vesicle preparation
Polymeric vesicles were prepared from palmi-
toyl glycol chitosan as previously described
(Uchegbu et al., 1998b). Egg PC liposomes were
prepared by dissolving egg PC (15 mg) and
Fig. 1. (a) Schematic representation of a polymeric vesicle in
liposome system; (b) schematic representation of the con-
trolled release properties offered by the vesicle in vesicle
system.
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Fig. 2. Palmitoyl glycol chitosan.
cholesterol (7 mg) in chloroform (10 ml) and the
solution evaporated to dryness under reduced
pressure at 40°C. The resulting thin lipid film was
then hydrated with water (5 ml) by shaking for 30
min at RT to yield a homogenous dispersion of
egg PC liposomes.
Polyhedral niosomes, so called because they
present in an unusual polyhedral shape are pre-
pared without cholesterol and the incorporation
of 50 mole% cholesterol into the formulation
gives rise to the more usual spherical niosomes
(Uchegbu et al., 1996, 1997). Polyhedral niosomes
were prepared by dissolving C16G2 (28 mg) and
dicetyl phosphate (1 mg) in chloroform (10 ml)
and evaporating the solution to dryness under
reduced pressure at 40°C. The resulting thin film
of surfactants was hydrated with water (4 ml) by
shaking for I h at 60°C.
Spherical niosomes were prepared by dissolving
C16G2 (14 mg), cholesterol (14 mg) and
dicetylphosphate (1 mg) in chloroform (10 ml)
and the solution evaporated to dryness under
reduced pressure at 40°C. The resulting lipid film
was hydrated with water by shaking for I h at
60°C.
2.3. Lipid:surfactant mixing experiments
Pyrene forms excited dimers (excirners) in a
concentration dependant manner and the excita-
tion of pyrene excimers at 340 nm leads to a
fluorescent emission at 477 nm, a red shift with
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respect to the emission due to pyrene monomers
(392 nm) (Galla and Hartmann, 1980; Pownall
and Smith, 1989). Hence by using pyrene tagged
lipids, any dilution of pyrene, as would occur on
transfer of pyrene lipids from one vesicle bilayer
to another, may be monitored by measuring the
ratio of pyrene excirner to monomer emission
(E:M) (Pownall and Smith, 1989). This is due to
the fact that a transfer of the pyrene label from
one lipid bilayer to another would lead to a
reduction in E:M. This method was used to
study the degree of mixing between the different
vesicle formulations that were to be used to pre-
pare the vesicle in vesicle system. The pyrene
concentration in compared systems was kept
constant.
Pyrene labelled polymeric vesicles were pre-
pared by dissolving palmitoyl glycol chitosan (8
mg), cholesterol (4 mg) and 10 (1-pyrene) de-
canoic acid (1.5 mg) in chloroform (5 ml). The
solution was evaporated to dryness under re-
duced pressure at 40°C and the resulting film
hydrated with water (4 ml). The dispersion so
obtained was then probe sonicated (Soniprobe
Instruments) for 22 min with the instrument
set at 20% of its maximum output.
Zero point four milliliters of pyrene labelled
polymeric vesicles were added to isopropanol
(3.6 ml) to produce a dispersion giving 100%
monomer emission and to water (3.6 ml) to pro-
duce a dispersion giving 100% excimer emission.
The emission spectra (350–550 nm) of these mix-
tures were recorded on a Perkin–Elmer LS-50B
scanning fluorimeter (excitation 340 nm) at 10
min intervals for 1 h and the E:M value com-
puted. The E:M ratio remained fairly constant
over the 1 h time period.
Zero point four milliliters of pyrene labelled
polymeric vesicles were also added to an aliquot
of unlabelled polymeric vesicles (1.2 ml), unla-
belled polyhedral niosomes (1.2 ml) or unlabelled
spherical niosomes (1.2 ml) and the emission
spectra and E:M value recorded as described
above.
The level of lipid mixing occurring during the
preparation of the vesicle in vesicle system was
assessed in the following way. A thin film of
surfactants: lipids was prepared as described
above using C16G2 (28 mg) and dicetyl phos-
phate (1 mg) to give polyhedral niosomes or
C16G2 (14 mg), cholesterol (14 mg) and dicetyl
phosphate (2mg) to give spherical niosomes. The
film was hydrated by shaking for 1 h at 60°C
with a dispersion (4 ml) of pyrene labelled poly-
meric vesicles consisting of palmitoyl glycol chi-
tosan (0.5mg·ml1), cholesterol (0.25 mg·ml1)
and 10-(1 -pyrene)decanoic acid (0.25 mM). The
E:M value was once again recorded as detailed
above. In a similar manner a thin film prepared
from egg PC (1 5 mg) and cholesterol (7 mg) to
give egg PC liposomes was hydrated by shaking
for 1 h at RT with pyrene labelled polymeric
vesicles (4 ml) and the E:M value once again
recorded.
2.4. Preparation of gold labelled polymeric
6esicles
A colloidal gold dispersion (20 nm, 6 ml) was
concentrated by centrifugation (9000g30 min,
Beckman L8-55M ultracentrifuge). The clear su-
pernatant was removed and discarded and the
colloidal gold collected and diluted to 2.5 ml,
with distilled water. To this colloidal gold disper-
sion was then added palmitoyl glycol chitosan (5
mg) and cholesterol (2 mg) and the entire mix-
ture probe sonicated as detailed above. To sepa-
rate unencapsulated gold from encapsulated gold
the mixture was further centrifuged (2200g5
min) and the pelletted unencapsulated colloidal
gold discarded. Gold-labelled polymeric vesicles
were visualised by electron microscopy as de-
tailed below.
2.5. Preparation of the 6esicle in 6esicle system
— encapsulation of gold labelled polymeric
6esicles within egg PC liposomes
A thin film of egg PC (8 mg) and cholesterol
(4 mg) was hydrated with the polymeric vesicle
suspension (2.5 ml) encapsulating colloidal gold
by shaking the mixture for 10 min at RT. In
some experiments polymeric vesicles encapsulat-
ing colloidal gold in which the unencapsulated
colloidal gold had not been removed were used
to prepare the vesicle in vesicle system.
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2.6. Electron microscopy
Freeze fracture electron microscopy was used to
visualise both the gold-labelled polymeric vesicles,
the gold-labelled vesicle in vesicle system and egg
PC liposomes. Specimens were fast-frozen by
plunging into liquid propane: isopentane at 
180°C and transferred cold into a high vacuum
freeze-fracture system. Specimens were fractured
with a Balzars complementary replica device at
100°C and the exposed faces replicated with
platinum carbon at 45° and backed by carbon at
90°. Replicas were cleaned in acetone: alcohol,
rinsed in distilled water, dried on Formvar-coated
grids and finally imaged using a LEO 902 energy-
filtering electron microscope.
Transmission electron microscopy with negative
staining was also used to visualise gold-labelled
polymeric vesicles. Droplets of vesicle preparation
were mixed in equal (20 ml) volumes with 1%
uranyl formate in distilled water (pH, 4.8) on a
specimen support grid and immediately dried
down using filter paper. The negatively stained
grid samples were imaged in a LEO 902 energy
filtering electron microscope at 8 kV.
2.7. CF loaded 6esicle in 6esicle system
CF loaded polymeric vesicles were prepared by
sonicating a dispersion of palmitoyl glycol chi-
tosan (16 mg) and cholesterol (8 mg) with a
solution of CF (2.2 mM, 8 ml). Separation of
unentrapped CF was achieved by ultracentrifuga-
tion (150 000g30 min) and the supernatant dis-
carded. The pelleted CF loaded vesicles were
resuspended in 5 ml phosphate buffered saline
(PBS, pH, 7.4). The CF loaded vesicle in vesicle
system was prepared by hydrating a thin film of
Egg PC (15 mg) and cholesterol (7 mg), with the
CF loaded polymeric vesicle dispersion (5 ml).
Hydration of the phospholipid cholesterol film
was achieved by shaking at RT for 1 h. Unencap-
sulated CF loaded polymeric vesicles were sepa-
rated by centrifugation (1400g30 min) and the
pelleted vesicle in vesicle system resuspended in
PBS (8 ml).
CF loaded egg PC liposomes were prepared by
hydrating an egg PC (15 mg) and cholesterol (7
mg) film with 5 ml, CF (2.2 mM). This was
carried out by shaking for 10 min at RT. The
assay for encapsulated CF was carried out as
previously described (Uchegbu et al., 1992).
The release of CF from (a) the vesicle in vesicle
system; (b) Egg PC liposomes; and (c) polymeric
vesicles was also studied. The three vesicle prepa-
rations were normalised for CF concentration and
a control sample of CF solution also prepared. 1
ml, aliquots of each of the vesicle formulations
and the control CF solution were placed in 10 cm
lengths of Visking dialysis tubing (Mw cut off
12 000–14 000) and both ends sealed. These were
then placed in 20 ml, PBS (pH, 7.4) and the
dialysate sampled at various time intervals. Re-
leased CF was quantified by fluorimetric analysis
(excitation, 486 nm, emission, 514 nm).
3. Results
3.1. Lipid:surfactant mixing experiments
On hydration of a lipid:surfactant film with the
polymeric vesicle formulation, mixing of the bi-
layer constituents would lead not to a vesicle in
vesicle system as desired, but a vesicle formulation
in which the bilayers were made up of mixtures of
lipids arising from both formulations. Hence an
assessment of the degree of mixing of both vesi-
cles comprising the vesicle in vesicle system was
deemed necessary.
The presence of the peak at 477 nm in pyrene
labelled polymeric vesicles (Fig. 3a) is indicative
of the presence of pyrene excimers, while the
presence of the peak at 392 nm (Fig. 3b) when the
labelled polymeric vesicles are disrupted with iso-
propanol is indicative of the presence of pyrene
monomers (Viani et al., 1988). It is clear from the
spectra (Fig. 3a and b) and respective E:M values
(Table 1) that the pyrene label was effectively
incorporated into the polymeric vesicle bilayer.
The formation of monomers on disruption of the
bilayer with isopropanol indicates that the pyrene
label was originally incorporated into the poly-
meric vesicle bilayer in discrete domains of local
high concentration. Once the bilayer was dis-
rupted by the solubilisation of cholesterol with
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Fig. 3. Emission spectra of pyrene labelled polymeric vesicle systems (excitation, 340 nm) a) in water (pyrene concentration, 0.1
mM); (b) disrupted with nine volumes of isopropanol (pyrene concentration 0.1 mM), c) incubated for 1h with unlabelled polymeric
vesicles (pyrene concentration 0.25 mM); (d) incubated for 1 h with unlabelled polyhedral niosomes (pyrene concentration, 0.25
mM). Emission spectra (excitation, 340 nm) of (e) a polyhedral niosome suspension prepared in the presence of pyrene labelled
polymeric vesicles; and (f) an egg PC liposome suspension prepared in the presence of pyrene labelled polymeric vesicles.
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Fig. 3. (Continued)
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Table 1
E:M values of pyrene labelled polymeric vesicles incubated for 1 h in various media
10-(1-Pyrene)decanoic acidE:M value Final concentration ofIncubation media
concentration (mM) surfactants:lipids (mg·ml1)
4.93Water 0.1mM 0.3
0.1mM0.06 0.3Isopropanol
0.73 0.25mMUnlabelled polymeric 5
vesicles
0.19Unlabelled polyhe- 0.25mM 5.3
dral niosomes
0.16 0.25mM 5Unlabelled spherical
niosomes
isopropanol these discrete domains were de-
stroyed and hence only the monomer peak was
seen (Fig. 3b, Table 1).
The transfer of the pyrene label from poly-
meric vesicle bilayers to non labelled vesicles and
hence the degree of lipid:surfactant mixing was
assessed by incubating pyrene labelled polymeric
vesicles with unlabelled niosomes. The level of
lipid:surfactant mixing was found to be lowest
when labelled polymeric vesicles were incubated
with unlabelled polymeric vesicles (Fig. 3c, Table
1) but highest when labelled polymeric vesicles
were incubated with polyhedral or spherical nio-
somes (Fig. 3d, Table 1). On preparing polyhe-
dral niosomes, spherical niosomes and egg PC
liposomes in the presence of pyrene labelled
polymeric vesicles, the level of lipid:surfactant
mixing as determined by the fall in E:M values
followed the trend egg PCBspherical nio-
somesBpolyhedral niosomes (Fig. 3e and f,
Table 2). There was obviously some transfer of
the pyrene label when labelled vesicles were incu-
bated with unlabelled vesicles but this was mini-
mal in two notable cases: (a) when labelled
vesicles were incubated with unlabelled polymeric
vesicles; and (b) when labelled polymeric vesicles
were used to hydrate an egg PC-cholesterol film.
3.2. Imaging of the 6esicle in 6esicle system
Colloidal gold effectively labelled the poly-
meric vesicles (Fig. 4a and b) and the presence
of gold labelled polymeric vesicles encapsulated
within larger Egg PC vesicles is shown in Fig.
4(c). Plain egg PC liposomes are shown in Fig.
4(d). Freeze fracture electron microscopy was
chosen as the imaging technique for the vesicle
in vesicle system since the fracturing of vesicles
during sample preparation is able to produce
images of the vesicle interior and hence clearly
show vesicles contained within vesicles. However
to obtain useful images both internal and exter-
nal vesicles require to be fractured simulta-
neously.
Table 2
E:M values of unlabelled formulations prepared in the presence of pyrene labelled polymeric vesicles
Formulation Final concentration of10-(I-Pyrene)decanoic acidE:M value
surfactants: lipids (mg·ml1)concentration (mM)
8.0Polyhedral niosomes 0.26 0.25mM
0.44 8.0Spherical niosomes 0.25mM
6.00.25mMEgg PC liposomes 0.57
D. McPhail et al. : International Journal of Pharmaceutics 200 (2000) 73–86 81
It is theoretically possible that any free unen-
capsulated gold may become entrapped within egg
PC liposomes during their formation. However, it
is more probable that the image obtained in Fig.
4(c) represents the gold labelled polymeric vesicles
entrapped within phosphatidylcholine vesicles as
this image shows a vesicle entrapped within a
vesicle and not simply a vesicle entrapping free
gold.
3.3. CF release
As these vesicle in vesicle systems are being
developed for the controlled release of bioactive
substances, the release of a model compound the
aqueous soluble fluorophore-CF from the vesicle
in vesicle system was studied (Fig. 5). Polymeric
vesicles released 62% of encapsulated CF after 4 h
compared to the release of 28% encapsulated CF
Fig. 4. (a) Freeze fracture electron micrograph of gold (20 nm) labelled polymeric vesicles, gold particles are indicated by arrow, bar,
250 nm; (b) Transmission electron micrograph with negative staining of gold (20 nm) labelled polymeric vesicles, gold particles are
indicated by arrows, bar, 400 nm; (c) Freeze fracture electron micrograph of large egg PC liposome encapsulating polymeric gold
(20 nm) labelled vesicle, gold particles are indicated by arrow, bar, 400 nm; (d) Freeze fracture electron micrograph of egg PC
liposomes, bar, 600 nm.
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Fig. 4. (Continued)
from the vesicle in vesicle system over the same
time period, evidence that the vesicle in vesicle
system retards the release of encapsulated solutes.
Egg PC liposomes released 37% of encapsulated
CF under similar conditions. The difference in the
release rate of CF when CF loaded polymeric
vesicles are compared to the sample in which CF
loaded polymeric vesicles were used to hydrate a
film of egg PC-cholesterol (Fig. 5) is indicative of
the polymeric vesicles being entrapped within the
egg PC liposomes.
4. Discussion
When taken collectively and not in isolation the
experimental data from each set of experiments
point to the fact that a vesicle in vesicle system
may be fabricated from polymeric vesicles and egg
PC liposomes. This work represents the first time
that vesicle prepared from one amphiphile have
been encapsulated within vesicles prepared from a
second amphiphile. Lipid:surfactant mixing ex-
periments were employed to select the formula-
D. McPhail et al. : International Journal of Pharmaceutics 200 (2000) 73–86 83
tion to be used to prepare the multicomponent
system and the formation of the vesicle in vesicle
system confirmed by electron microscopy.
Egg PC is an ideal material for formulation of
the outer component of the vesicle in vesicle sys-
tem by virtue of the low gel to liquid phase
transition temperature of this phospholipid (New,
1990). Hence vesicles may be prepared by film
hydration at room temperature (Fig. 4d) and once
formed are quite stable at room temperatue (RT).
Bilayer phospholipids are known to be more mo-
bile at elevated temperatures (Israelachvili, 1992)
and as such elevated temperatures during prepara-
tion of the vesicle in vesicle system would be more
likely to result in perturbation of the polymeric
vesicle membrane by phospholipid molecules.
Preparation of egg PC vesicles in the presence of
polymeric vesicles at RT would also limit the
mobility in the polymeric vesicle bilayer and once
again reduce the likelihood of intervesicular bi-
layer mixing.
The preparation of both cholesterol containing
formulations, i.e. the spherical niosomes and the
egg PC liposomes in the presence of pyrene la-
belled polymeric vesicles revealed a greater degree
of lipid mixing in the case of the spherical nio-
somes than the egg PC liposomes (Table 2). It is
possible that this could be due to the lower level
Fig. 4. (Continued)
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Fig. 4. (Continued)
of overall lipid:surfactant in the egg PC system.
This is unlikely however, as the lipid mixing in the
polyhedral and spherical niosome systems is fur-
ther enhanced at lower overall lipid concentra-
tions (Table 1). The lower degree of lipid mixing
in the egg PC system could also be due to the
molecular differences between C16G2 and egg PC.
C16G2 is a single tailed amphiphile while egg PC
consists of a mixture of largely double tailed
amphiphiles (Fig. 6). The inter-bilayer transfer of
the double tailed amphiphile would be a higher
energy process than the transfer of the single
tailed amphiphile since this transfer will involve a
crossing of the external aqueous layer (Pownall
and Smith, 1989). Hence perturbation of the poly-
meric vesicle bilayer by phospholipid molecules
with the resultant inter-vesicular bilayer mixing
would occur less readily with the egg PC system
when compared to the C16G2 system. However the
essential conclusion to be drawn for the data in
Table 2 is that egg PC liposomes appear to be a
Fig. 5. The release of CF (0.03 mM) from (), vesicle in
vesicle system (polymeric vesicles encapsulated in egg PC
liposomes), 	, egg PC liposomes; , polymeric vesicles;
,
CF solution.
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Fig. 6. Structural formulae for (a) C16G2; and (b) a typical phospholipid component of egg PC.
better choice for the external vesicles than any of
the C16G2 systems.
A comparison of the level of lipid:surfactant
mixing observed when pyrene labelled polymeric
vesicles were incubated with either unlabelled
polymeric vesicles or unlabelled spherical nio-
somes, both of which contain cholesterol at a level
of 33%w:w, revealed less lipid:surfactant mixing
in the case of the polymeric bilayers (Table 1).
This suggests that the polymeric bilayer is a less
mobile environment when compared to the spher-
ical niosome bilayer.
The formation of a vesicle in vesicle system
(Fig. 4c) provides a greater control of the release
rate of encapsulated solutes as shown in Fig. 5
due to the fact that the aqueous solute has to
cross at least two well defined membrane barriers
(Fig. 1b). This can be used to provide controlled
release immunological adjuvants or anti-cancer
formulations. However more importantly the vesi-
cle in vesicle system may be used to incorporate
two different active ingredients as for example in
combination chemotherapy or the for the incor-
poration of an enzyme within one compartment
and a prodrug within a second compartment for
site specific activation. These applications will be
explored in subsequent studies.
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